Inhibitors of lysine specific demethylase-1

Patent metadata

Field	Value
Publication number	US-10626104-B2
Application number	US-201916289278-A
Country	US
Kind code	B2
Filing date	Feb 28, 2019
Priority date	Jul 3, 2014
Publication date	Apr 21, 2020
Grant date	Apr 21, 2020

Abstract

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of lysine specific demethylase-1. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

First claim

We claim:

1. A method of treating prostate cancer in a patient in need thereof, comprising administering to the patient a therapeutic effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof,

wherein,
A is C; B is N; and D is C—R 3 ;
R 3 is hydrogen;
W 1 and W 2 are C—H;
X is chosen from aryl optionally substituted with halogen, alkyl, or alkoxy; or heteroaryl optionally substituted with halogen, alkyl, alkoxy, or cycloalkyl;
Y is chosen from hydrogen, halogen, alkyl optionally substituted with —OH, alkoxy, or carbonyl; and
Z is N-heterocyclyl optionally substituted with —NH 2 , amine, or alkyl.

2. The method of claim 1 , wherein X is aryl optionally substituted with halogen, alkyl, or alkoxy.

3. The method of claim 2 , wherein the aryl is phenyl.

4. The method of claim 1 , wherein X is heteroaryl optionally substituted with halogen, alkyl, alkoxy, or cycloalkyl.

5. The method of claim 4 , wherein the heteroaryl is chosen from pyridinyl, pyrimidinyl, pyrazinyl, pyrazolyl, indazolyl, azaindazolyl, isoindazolyl, indolyl, or azaindolyl.

6. The method of claim 1 , wherein Z is N-heterocyclyl optionally substituted with —NH 2 , amine, or alkyl and the N-heterocyclyl is a 4-, 5-, 6-, or 7-membered N-heterocyclyl.

7. The method of claim 6 , wherein the N-heterocyclyl is a 6-membered N-heterocyclyl.

8. The method of claim 7 , wherein the N-heterocyclyl is piperidine.

9. The method of claim 8 , wherein the piperidine is 3-aminopiperidine.

10. The method of claim 6 , wherein the N-heterocyclyl is a 5-membered N-heterocyclyl.

11. The method of claim 10 , wherein the N-heterocyclyl is pyrrolidine.

12. The method of claim 11 , wherein the pyrrolidine is 3-aminopyrrolidine.

13. The method of claim 1 , wherein Y is hydrogen.

14. The method of claim 1 , wherein Y is halogen.

15. The method of claim 1 , wherein Y is alkyl optionally substituted with —OH, alkoxy, or carbonyl.

16. The method of claim 15 , wherein the alkyl is C 1 -C 3 alkyl.

17. The method of claim 15 , wherein the alkyl is C 1 alkyl.

Assignees

• Celgene Quanticel Res Inc

Inventors

• Chen Young K
• Kanouni Toufike
• Nie Zhe
• Stafford Jeffrey Alan
• Veal James Marvin

Classifications

• C07D401/06 Primary

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D403/14

  containing three or more hetero rings · CPC title

• C07D401/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D487/10

  Spiro-condensed systems · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title